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 Cryptosporidium is a major cause of moderate to severe diarrhea in humans worldwide, 
second only to rotavirus. Due to the wide host range and environmental persistence of this 
parasite, cryptosporidiosis can be zoonotic and associated with foodborne and waterborne 
outbreaks. Currently, 31 species are recognized as valid and of these, Cryptosporidium 
hominis and Cryptosporidium parvum are responsible for the majority of infections in 
humans. The immune status of the host, both innate and adaptive immunity, has a major 
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typically experience self-limiting diarrhea and transient gastroenteritis lasting up to 2 weeks 
and recover without treatment, suggesting an efficient host anti-parasite immune response. 
Immunocompromised individuals can suffer from intractable diarrhea, which can be fatal. 
Effective drug treatments and vaccines are not yet available. As a result of this, the close 
cooperation and interaction between veterinarians, health physicians, environmental 
managers and public health operators is essential to properly control this disease. This review 
focuses on a One Health approach to prophylaxis, including the importance of understanding 
transmission routes for zoonotic Cryptosporidium species, improved sanitation and better risk 
management, improved detection, diagnosis and treatment and the prospect of an effective 
anti-cryptosporidial vaccine. 
 




Cryptosporidium species are protozoan parasites that infect a broad range of hosts 
including humans, domestic and wild animals worldwide, causing asymptomatic or mild to 
severe gastrointestinal disease in their host species (1-6). Currently, 31 Cryptosporidium 
species have been recognised as valid and of these, by far the most common species reported 
in humans worldwide are C. parvum and C. hominis (7-12). 
Human cryptosporidiosis is frequently accompanied by abdominal pain, fever, 
vomiting, malabsorption and diarrhea that may sometimes be profuse and prolonged (13, 14). 
The immune status of the host, both innate and adaptive immunity, has a major impact on the 
severity of the disease and its prognosis. Immunocompetent individuals typically experience 
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treatment, suggesting an efficient host anti-parasite immune response. Immunocompromised 
individuals including HIV/AIDS patients (not treated with antiretroviral therapy), often suffer 
from intractable diarrhea, which can be fatal (15). An effective vaccine for cryptosporidiosis 
is not yet available. 
 
The Global Enteric Multicenter Study (GEMS) study, which was a three year matched 
case-control study of moderate-to-severe diarrhea in over 22,000 infants and children at seven 
sites across Africa and Asia aged 0-59 months, found that Cryptosporidium was second only 
to rotavirus as a major cause of severe diarrhea (16, 17). More recent matched case-control 
studies of diarrhea have confirmed this (18). Similarly, a birth cohort study conducted by a 
Global Network for the Study of Malnutrition and Enteric Diseases (MAL-ED), has assessed 
pathogen-specific burdens in diarrheal and nondiarrheal stool specimens from 2,145 children 
aged 0-24 months, over five years at eight community sites in Africa, Asia and South 
America, and identified Cryptosporidium spp. as one of the five highest attributable burdens 
of diarrhoea in the first year of life (19). Globally, cryptosporidiosis is estimated to be 
responsible for the majority of deaths among children under 5 years of age (20-22) and 
Cryptosporidium infection in children is also associated with malnutrition, persistent growth 
retardation, impaired immune response and cognitive deficits (23, 24). The mechanism by 
which Cryptosporidium affects child growth seems to be associated with inflammatory 
damage to the small intestine (25). Undernutrition (particularly in children) is both a sequela 
of- and a risk factor for- cryptosporidiosis, particularly in low-income countries (26-31). 
FAO’s executive summary of the State of Food Insecurity in the World 
(http://www.fao.org/docrep/018/i3458e/i3458e.pdf) indicates there are 842 million 
chronically malnourished persons worldwide, which significantly contributes to impaired 
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the cycle of chronic diarrhea and malnutrition. In developed countries, Cryptosporidium is 
less common (15) and accounts for ~9% of diarrheal episodes in children (32). 
Cryptosporidiosis is a highly prevalent and extremely widespread disease (6) and 
several factors contribute to this. Infected individuals shed large numbers of oocysts, which 
are environmentally very robust, resistant to inactivation by commonly used drinking water 
disinfectants including chlorine treatment and are able to survive routine wastewater 
treatments (33, 34). Cryptosporidium oocysts are highly infectious; in human volunteer 
studies, as few as 10 or less Cryptosporidium oocysts can produce disease in healthy adults 
(35, 36). A quantitative risk assessment has estimated that ingestion of a single oocyst of the 
C. parvum IOWA isolate will result in clinical disease in 2.79% of immunologically normal 
persons (37). Another contributing factor to the high prevalence and widespread distribution 
of Cryptosporidium is the lack of treatment options. Only one drug, nitazoxanide (NTZ, 
Alinia; Romark Laboratories, Tampa, Florida, United States), has been approved by the 
United States (US) Food and Drug Administration (FDA). This drug, however, exhibits only 
moderate clinical efficacy in malnourished children and immunocompetent people, and none 
in immunocompromosed individuals like people with HIV (38, 39).  
Because oocysts of Cryptosporidium species from humans and animals are ubiquitous 
in the environment, cryptosporidiosis can be acquired through multiple routes (reviewed by 
Robertson et al. 40). Transmission of oocysts is by the faecal-oral route, either directly or 
indirectly. For humans, direct transmission can be from person to person primarily due to 
poor hygiene among household members and attendees in day-care centers, aged care 
facilities and other institutions, or from animals to persons such as farm-workers and pet 
owners. Most indirect transmission is from contaminated drinking or recreational water. 
Contaminated food can also be a source of transmission and contamination can occur at every 
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animal models, human case reports, and a few epidemiological studies suggest that 
Cryptosporidium may also be transmitted via inhalation of aerosolized droplets or by contact 
with fomites contaminated by coughing (see 43).  
The “One Health” approach to tackle zoonotic diseases defined as "One Medicine" by 
Schwabe (1984), is a worldwide strategy to improve health and well-being through the 
mitigation and prevention of disease risks that originate at the interface between humans, 
animals and their various environments (44). This review focuses on a One Health approach 
to prophylactic prevention of cryptosporidiosis including improved detection, diagnosis and 
treatment, the importance of understanding zoonotic transmission, better environmental and 
risk management and the prospect of an effective anti-cryptosporidial vaccine. 
 
DETECTION, DIAGNOSIS AND TREATMENT 
 Cryptosporidium presents many challenges for detection and diagnosis. The use of 
different diagnostic methods and the inconsistent application of typing techniques can make 
direct comparisons difficult or even impossible between clinical, veterinary and 
environmental testing or 
between different regions or countries (45). Detection of Cryptosporidium in clinical 
pathology laboratories is still based mainly on microscopic detection via stains and/or 
fluorescent antibodies (IFA) and other antigenic detection methods. Although microscopy 
needs relatively simple instruments and cheap consumables, it is labour intensive, requires a 
skilled operator and lacks sensitivity and specificity (45). Morphological characters for 
identifying Cryptosporidium are few (46, 47) and differential staining techniques are usually 
required due to the fact that oocysts are similar in size and shape to yeasts, fecal components 
and other debris (47, 48). Acid fast (AF) modified Ziehl–Neelsen staining is one of the most 
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conventional microscopy for Cryptosporidium have been reported to be as low as 50, 000 to 
500, 000 oocysts per gram of human faeces (49), resulting in low levels of infection or 
sporadic shedding possibly going unnoticed when conventional methods of detection are 
used. Sporadic sheding is such that studies have shown that three separate faecal samples 
should be examined for immunocompetent patients and two samples for AIDS patients for 
confident diagnosis of cryptosporidial infections using acid-fast staining (50). IFA stains 
offer superior sensitivity; in some studies, about 97% sensitivity compared with only about 
75% sensitivity for acid-fast staining (51). However, IFA is more expensive than acid-fast 
staining and requires a fluorescence microscope and trained staff (51). This is particularly 
problematic in resource-poor areas where cryptosporidiosis is a major health problem. A 
recent study proposed the use of phase contrast microscopy (PCM) as a specific and 
inexpensive method for detection of Cryptosporidium, however this method still lacks 
sensitivity (52). 
Other antigen detection formats such as enzyme linked immunosorbent assays 
(ELISA’s), enzyme immunoassays (EIA’s) and immunochromatographic (dipstick) assay for 
Cryptosporidium are also commercially available and have the advantage of reducing assay 
times and being amenable to automation. However, diagnostic sensitivities are variable (70% 
to 100%) (51, 53-55); some rapid tests have reduced specificity and sensitivity for species 
other than C. parvum or C. hominis (56, 57) and confirmation of positive reactions is needed 
(55). Biosensor chips, that detect and quantitate C. parvum in real-time via anti-C. parvum 
IgM binding have also been developed (58, 59), however detection limits are relatively high 
(100 or more oocysts) and they have yet to be fully evaluated on water or faecal samples. 
Another major limitation of both conventional microscopy and antigen detection methods is 
that they cannot identify to species or subtype level, which is essential for understanding 
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 Polymerase chain reaction (PCR)-based techniques have permitted specific and 
sensitive detection and differentiation of Cryptosporidium spp. for clinical diagnosis and 
environmental monitoring (45). Real-time or quantitative PCR (qPCR) assays been 
developed to quantitate the numbers of Cryptosporidium oocysts present in human and 
animal faecal and water samples (60-63) with 100% specificity and sensitivies as low as 200 
oocysts per gram of faeces, which equates to 2 oocysts per PCR (60). Multiplex qPCR assays 
have also been developed for the detection of Cryptosporidium and other common causes of 
diarrhoea such as Giardia duodenalis and Entamoeba histolytica, which have the advantage 
of identifying mixed infections (64-66). The most widely used molecular markers for 
identification and typing of Cryptosporidium species are the 18S ribosomal RNA (18S 
rRNA) gene and the 60-kDa glycoprotein (gp60) gene respectively (4, 10). Miniaturised 
fluidic devices, which can detect to species level have also been developed, mainly for the 
water industry, (reviewed by Bridle et al. 67), but as with antibody-based biosensor chips, 
have yet to be fully validated and are costly.  
 New drug targets for Cryptosporidium are urgently needed, as the only FDA-approved 
drug, nitazozanide, does not provide benefit for malnourished children and 
immunocompromised patients with cryptosporidiosis. However, Cryptosporidium has 
completely lost the plastid-derived apicoplast present in many other apicomplexans, and the 
remnant mitochondrion lacks the citrate cycle and cytochrome-based respiratory chain (68). 
Therefore, many classic drug targets are unavailable in Cryptosporidium. Progress in 
developing anti-cryptosporidial drugs has also been affected by the inability to generate large 
numbers of Cryptosporidium oocysts in vitro and an inability to genetically manipulate the 
organism (69, 70). The recent development of a hollow fiber in vitro culture system to 
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genetically engineering Cryptosporidium (72), will transform the development of novel 
therapeutics.  
 To date, the best studied drug target is the bacterial derived inosine 5’ - monophosphate 
dehydrogenase (IMPDH) gene, as Cryptosporidium does not contain guanine salvage 
enzymes and is totally dependant on this enzyme to convert adenosine salvaged from the host 
into guanine nucleotides (69, 74-76). This coupled with the parasite’s high metabolic demand 
for nucleotides due to the complicated lifecycle of this parasite make IMPDH an important 
drug target (77-85).  
 Other drug targets include long chain fatty acyl-coenzyme A synthetases (LC-ACS) 
which are essential in fatty acid metabolism (68) and a recent study reported good efficacy of 
the ACS inhibitor triacsin C against cryptosporidial infection in mice (86). A parasite 
cysteine protease inhibitor was also effective in vitro and in an animal model (87). Other 
studies have focused on repurposing existing drugs to overcome the prohibitive costs of de 
novo drug development (estimated to be between $500 million and $2 billion per compound 
successfully brought to market) (88). For example, several compounds from the Medicines 
for Malaria Venture (MMV) Open Access Malaria Box have exhibited activity against C. 
parvum (89) and drugs such as the human 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-
CoA) reductase inhibitor, itavastatin and Auranofin (Ridaura®) initially approved for the 
treatment of rheumatoid arthritis and have been shown to be effective against 
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ZOONOTIC CRYPTOSPORIDIUM SPECIES 
Due to the morphological similarity of Cryptosporidium oocysts from different host 
species, initial findings of Cryptosporidium infections in both domestic and wild animals 
were assumed to be due to C. parvum leading to an overestimation of the potential role of 
animals as reservoirs of human disease (92). However, with the assistance of advanced 
molecular techniques, many of these species in wildlife particularly were identified as host-
adapted genotypes (6, 10). Of the 31 Cryptosporidium species that have been recognised as 
valid, more than 20 species and genotypes have been identified in humans including C. 
hominis, C. parvum, C. meleagridis, C. felis, C. canis, C. cuniculus, C. ubiquitum, C. 
viatorum, C. muris, C. suis, C. fayeri, C. andersoni, C. bovis, C. scrofarum, C. tyzzeri, C. 
erinacei and Cryptosporidium horse, skunk and chipmunk I genotypes, with C. hominis and 
C. parvum most commonly reported (4, 6, 10). These Cryptosporidium spp. infect both 
immunocompetent and immunocompromised persons (6, 10). Of these, C. parvum and C. 
hominis are by far the most common species reported in humans worldwide (4, 93) and are 
responsible for most cryptosporidiosis outbreaks, with C. hominis responsible for more 
outbreaks than C. parvum in most regions (4). Although humans are the major host species for 
C. hominis, there have been isolated reports in domestic animals and wildlife hosts including 
sheep, goats, cattle, a dugong, non-human primates and kangaroos (94-102, Zahedi et al., 
unpublished) and in fish (103). Cryptosporidium parvum is primarily a parasite of 
artiodactyls and humans (4) but has also been frequently reported in wildlife, including 
various rodents, bovids, camelids, equids, canids, non-human primates and marine mammals 
(see 10) and in fish (103-106). Cryptosporidium meleagridis, although primarily a bird 
parasite, is the third most prevalent species infecting humans (4, 6, 93) and in some studies, 
C. meleagridis prevalence is similar to that of C. parvum (107, 108). Cryptosporidium 
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associated outbreak of cryptosporidiosis in the UK (109-111) and has also been identified in 
many sporadic human cases of cryptosporidiosis (112-115). It is also the third most 
commonly identified Cryptosporidium species in patients with diarrhoea in the UK (112). 
Human infections with C. canis and C. felis have been reported mainly in studies conducted 
in children in developing countries (6) where they are responsible for as much as 3.3 and 
4.4%, respectively, of overall cryptosporidiosis cases (116). Cryptosporidium muris is also 
considered a zoonotic species as there have been numerous reports of C. muris in humans and 
one report in human sewage (117-129). In a recent human infectivity study, C. muris was 
examined in six healthy adults (130). Volunteers were challenged with 105 C. muris oocysts 
and monitored for 6 weeks for infection and/or illness. All six patients became infected. Only 
two of the infected volunteers had a diarrheal illness (a 33% illness attack rate). Three other 
volunteers passed an occasional unformed stool or typically had a single soft stool per day 
without any accompanying gastrointestinal symptoms (130). Like C. muris, C. andersoni is 
also a gastric parasite and primarily infects the abomasum of cattle and to a lesser extent, 
sheep and goats (6, 93). It is occasionally detected in humans (cf. 10). Two studies in China 
by the same research group have reported that C. andersoni was the most prevalent 
Cryptosporidium species detected in humans (131-132). However, further research is 
required to better understand the zoonotic importance of C. andersoni. 
Cryptosporidium ubiquitum is of public health concern because of its wide geographic 
distribution and broad host range (133). It has been frequently reported from drinking source 
water and wastewater in various geographic locations, and is considered an emerging 
zoonotic pathogen as it has been identified in many human cases of cryptosporidiosis (133). 
Subtyping at the gp60 locus has suggested that sheep and wild rodents are a key source of C. 
ubiquitum transmission to humans, through either direct human contact with infected animals 
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into wildlife territories has been responsible for the emergence of C. ubiquitum and other 
genotypes like chipmonk genotype I and to a lesser extent, skunk and mink genotypes in 
human populations (133-143). This highlights the importance of extensive molecular 
epidemiological studies of wildlife to better understand the public health risks. 
 
RISK MANAGEMENT  
A key part of a One Health approach to Cryptosporidium prophylaxis is a better 
understanding of environmental, epidemiological and aetiological factors associated with 
cryptosporidial infections to enable more targeted risk management. The far-reaching One 
Health strategy aims at integrating multidisciplinary knowledge and evidence, and at 
coordinating the intervations, in order to create a global synergism catering for all aspects of 
health-care for humans, animals and the environment (the One Health Triad).  
 Under an environmental perspective, the prophylaxis of waterborne cryptosporidiosis 
must consider optimal management (or design) of source, recycled‒ and recreational‒ waters. 
Protection of source water and swimming pools is a key element of Cryptosporidium 
prevention as contamination of drinking water and swimming pools is a major mode of 
transmission (see ref 33, 144, 145) and is often achieved by restricting the access to catchments 
and water bodies, while swimming pools are designed and monitored according to 
construction standards and guidelines. Infection prevention and management however, can 
only be achieved through a deep understanding of the routes of transmission, sources of 
contamination (human and animal), disease prevalence in the population, and the risk factors 
in the final host.  
The link between Cryptosporidium in drinking water and sporadic infections is well 
documented (33, 144, 145), however, the association between drinking water contamination 
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drinking unsafe water as a risk factor for endemic cryptosporidial infection (146, 147) and 
others report no association (148-150). Seasonal patterns are also thought to be associated 
with an increased transmission risk (151, 152), such as when recreational waters are more 
heavily utilised. 
High precipitation events favor the transfer and survival of oocysts in surface waters 
and/or groundwater (153, 154). This may result in contamination of source water and 
increased risk of cryptosporidiosis depending on the source of contamination (154). Indeed, 
the average odds of identifying Cryptosporidium oocysts in fresh surface waters is 2.61 (95% 
CI = 1.63-4.21; I² = 16%) times higher during and after extreme weather events (155). Shifts 
in precipitation patterns (intensity and location) is one of the climate change predictions for 
the future (156) and this will clearly impact both waterborne and foodborne transmission of 
Cryptosporidium and therefore future human exposures may differ significantly from current 
patterns as the climate changes (157). Hydrodymanic modelling has been shown to represent 
a valid and cost-effective support, for decision making and understanding of events (158). 
Quantitative microbial risk assessment (QMRA), is another widely used tool to estimate 
health impacts from exposure to Cryptosporidium and other pathogens (155) and has been 
applied to climate change (159). The tool, called CC-QMRA (Climate Change Quantitative 
Microbial Risk Assessment), quantifies the anticipated impacts in terms of relative infection 
risks under climate change scenarios for Cryptosporidium and other pathogens and can be 
used to evaluate impacts of climate change on infection risks from waterborne and foodborne 
transmission of Cryptosporidium (160). For example, CC-QMRA can be used to evaluate the 
effectiveness of interventions such as upgrading wastewater and drinking water treatment and 
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Quantitatification and identification of Cryptosporidium in wildlife excreta is an 
essential starting point for estimating catchment loads (161). Variables such as soil physico-
chemical properties, hydrology, orography, meteorology etc. can all afftect oocyst viability, 
transport and fate. Source water contamination can be avoided or reduced by the 
implementation of management strategies like wildlife population control, revegetation, 
landscaping and soil conditioning. In addition, effective risk management cannot overlook 
the prevalence, infectivity and zoonotic potential of Cryptosporidium isolates in the animal 
populations within the catchment. Similarly, recreational waters like swimming pools, sauna, 
spas, aquatic parks etc. are also potential sources of outbreaks, depending on the age and 
health status of the users (and maintenance). Personal hygiene practices (e.g. showering 
before swimming in public swimming pools, washing hands before cooking, eating and after 
defecation and washing fruits and vegetables before consumption), are an essential part of 
any prevention strategy and can prevent/reduce disease transmission (162-165). Enforcing 
and encouraging similar practices, however, becomes absolutely crucial during outbreaks and 
in the presence of hyper-susceptible final hosts. 
It has been shown that an important host risk factor includes HIV status. 
Cryptosporidium is an important pathogen regardless of HIV-prevalence (16), however HIV-
positive children are between 3 and 18 times more likely to have Cryptosporidium than those 
who were HIV-negative (166-168). With the widespread availability of antiretroviral therapy, 
particularly in industrialised countries, the incidence of cryptosporidiosis has decreased 
among people living with AIDS (169). However, the increasing number of transplant 
recipients and those receiving immunosuppressive drugs may contribute significantly to the 
burden in the future (170, 171). Malnutrition is also a risk factor for both diarrhea and 
prolonged diarrhea caused by Cryptosporidium, with significantly higher rates of infection in 
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individuals experience asymptomatic Cryptosporidium infection (176). This clinically silent 
infection may remain undetected and untreated and therefore may contribute not only to 
parasite transmission but also to malnutrition and the associated clinical sequalae. Breast-
feeding may provide some protection, as a recent study of Bangladeshi infants reported that 
protection from Cryptosporidium infection was associated with high anti-Cryptosporidium 
IgA in breast milk (177).  
  
VACCINES 
The development of vaccines for cryptosporidiosis, particularly in vulnerable 
populations such as children and malnourished populations is urgent, but has been hampered 
by an incomplete understanding of the host immune response to Cryptosporidium (178, 179). 
Therefore, a better understanding of host-parasite interactions is crucial for the development 
of an effective vaccine (178). Given that adults in highly endemic areas are partly immune to 
reinfection; and human challenge studies have shown that previous infection or exposure 
leads to a higher infectious dose [ID50] (180, 181), development of a successful vaccine 
should be possible. It is known that both innate and adaptive host response are important in 
the control of Cryptosporidium infection (182-184). Yet the nature of these responses, 
particularly in humans, is not completely understood (179, 185).   
 Early mediators of innate immune protection include the thick mucus layer of the small 
intestine, intestinal epithelial cells and chemokines, cytokines and antimicrobial peptides 
secreted into the intestinal lumen and/or underlying submucosa and bloodstream (179). 
Important cytokines include interferon gamma (IFN-γ), which is secreted early in infection 
by natural killer (NK) cells, macrophages and dendritic cells which are thought to play a 
major role in orchestrating both the innate and adaptive immune responses (179, 183). Th1 
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resistance and recovery to Cryptosporidium infection (186-191). Treatment of both 
immunocompetent and immunodeficient mice with IL-12 before infection prevented or 
greatly reduced the severity of infection and was attributed to a decrease in IFN-γ reduction 
(191). Data suggests that IL-15 has an important role in activating an NK cell-mediated 
pathway that leads to the elimination of Cryptosporidium from the intestine (187). IL-18 is 
produced by epithelial cells in the gut and a number of different immune cells and is 
upregulated in response to C. parvum infection and it has been proposed that one of the 
functions of IL-18 is to promote IFN-γ expression by macrophages (188). Toll-like receptors 
expressed by epithelial cells have been shown to be important in modulation of the host 
immune response and subsequent parasite clearance (192-198).  
 MicroRNA (miRNA) regulation also appears to play an important role in host cell 
protection against Cryptosporidium (199-204). miRNA are small RNA molecules of 23 
nucleotides that result in gene silencing via translational suppression or mRNA degradation 
and are a mechanism to fine-tune cellular responses to the environment, and may be 
regulators of host anti-microbial immune responses (202). More than 700 miRNAs have been 
identified in humans and are postulated to control 20-30% of human genes. miRNA-mediated 
post-transcriptional gene regulation may regulate expression of genes critical to epithelial 
anti-microbial defense and one cellular miRNA (let-7i) has been shown to target Toll-like 
receptor 4 (TLR4) and regulate TLR4-mediated anti-C. parvum defense (199). Functional 
manipulation of select miRNA expression levels in epithelial cells has been shown to alter C. 
parvum infection burden in vitro (202, 203). The intercellular adhesion molecule-1 (ICAM-1; 
CD54) is a 90 kDa member of the Ig superfamily expressed by several cell types including 
endothelial cells and epithelial cells and is thought to facilitate adhesion and recognition of 
lymphocytes at infection sites as ICAM-1 is constitutively present on endothelial cells and 
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microbe infection. Evidence has shown that miR-221-mediated translational suppression 
controls ICAM-1 expression through targeting the ICAM-1 3′-untranslated region (UTR), in 
epithelial cells in response to C. parvum infection, as transfection of an miR-221 precursor in 
an vitro model of human biliary cryptosporidiosis abolished C. parvum-stimulated ICAM-1 
protein expression (202).  
 Mannose-binding lectin (MBL) is an evolutionarily conserved protein, secreted by 
hepatocytes, that functions in human innate immunity by binding to microbial surfaces and 
promoting opsonophagocytosis. MBL has been shown to be important in the protection 
against cryptosporidiosis, as children and HIV-infected adults with mannose-binding lectin 
deficiency have increased susceptibility to cryptosporidiosis and more severe disease (205-
207). The genetic contribution to deficient or low serum levels of MBL results from 
polymorphisms in the MBL2 gene (MBL1 is a pseudogene), which create low MBL-
producing MBL2 genotypes in ~5% of the world’s population (207). In one study on a cohort 
of preschool children from Dhaka, Bangladesh, polymorphisms in the MBL2 gene (and 
corresponding haplotypes) and deficient serum levels of MBL were associated with increased 
susceptibility to infection with Cryptosporidium. MBL deficiency of <500 ng/mL was 
associated with single and multiple symptomatic episodes of Cryptosporidium infection, with 
an OR of 7.6 for children with multiple symptomatic infections with Cryptosporidium (207). 
The mechanism by which MBL controls Cryptosporidium infection and protects children 
from it is still not clearly understood. 
Adaptive immunity creates immunological memory after an initial response to 
Cryptosporidium and leads to an enhanced response to subsequent encounters with 
Cryptosporidium. For example, antibodies to the parasite antigen gp15 were associated with 
protection against reinfection (208). The adaptive immune response to Cryptosporidium is 










This article is protected by copyright. All rights reserved. 
immune response during Cryptosporidium infection is highlighted by the susceptibility of 
AIDS patients to cryptosporidiosis, as well as the resolution of infection observed following 
CD4+ T lymphocyte cell reconstitution in patients given antiretroviral therapy (185, 209). 
Low absolute CD4+ T cell counts in patients with HIV/AIDS were thought to be responsible 
for persistent and severe cryptosporidiosis, however research with Simian immunodeficiency 
virus (SIV)-infected macaques reported that persistent cryptosporidiosis was more dependant 
on SIV load and profound viral damage to gut lymphoid tissue and rapid depletion of 
mucosal CD4+ T cells during the acute phase of viral infection, than on declining circulating 
CD4+ T cell levels during chronic SIV infection (210). This suggests that depletion of local 
CD4+ T cells may be more predictive of disease severity than absolute CD4+ T cell numbers. 
The importance of other T cells such as CD8+ have not been extensively studied but do 
appear to play a role (179). The role of humoral immunity in protection from 
cryptosporidiosis is not well understood and no clear surrogate marker of protective 
immunity exists (reviewed in 46 and 179).  
 The ideal Cryptosporidium vaccine should provide rapid life-long immunity in all 
vaccinated individuals, be broadly protective against the most common species and subtypes 
of Cryptosporidium, prevent disease transmission, and be readily accessible, stable, and 
cheap (178, 179). Ensuring cross-reaction against the most common species infecting humans 
however will be difficult, as more than 20 Cryptosporidium species and genotypes can infect 
humans as discussed above. For example, a recent study showed that infection of gnotobiotic 
pigs with C. hominis resulted in complete protection against subsequent infection with C. 
hominis, but incomplete protection against infection with C. parvum (211), therefore multiple 
species will need to be targeted to provide sufficient cross-protection. In addition, as children, 
malnourished and immunocompromised individuals are the most important vaccine targets, 
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response to vaccination. Indeed, malnutrition has been cited as an important factor underlying 
limited efficacy of vaccines (212). It is therefore likely that adjuvants such as TLR ligands 
(213), will be required to enhance the immune-response in target populations (193, 196). 
Several antigens, aimed at raising immunoglobulin G antibodies, are being developed 
as vaccine candidates (178). Some of the best studied are gp15 (214-219), cp15 (220-225) 
and cp23 (223, 226, 227). The gp15 antigen is derived from the glycoprotein gp60, which is 
cleaved by a parasite serine proteinase into two surface proteins - gp15 and gp40, both of 
which play an essential role in parasite motility and attachment to and invasion of host 
epithelial cells (228), and can stimulate interferon γ production by peripheral blood 
mononuclear cells of those previously infected (214), The gp15 antigen is relatively 
conserved between C. parvum and C. hominis, and studies in Bangladesh indicated that there 
is significant cross-reactivity between them and that antibodies to gp15 were associated with 
shorter duration of illness (217). Similarly, in a study in Kenya, AIDS patients without 
diarrhea had significantly higher serum IgG levels to gp15 than those with diarrhea (229).  
 cp15 is an immunodominant protein present on the oocyst surface and is associated 
with internal structures and bears no apparent similarity to gp15 (228). Immunisation of 
pregnant goats with cp15 vaccines protected off-spring (230). The impact of malnutrition 
however on vaccination was demonstrated in recent research on intranasal vaccination of 
nourished and malnourished mice, with the cp15 antigen primed with a live enteric bacterial 
vector (225). The authors reported that malnutrition blunted antigen-specific cell-mediated 
responses to cp15 and that vaccination resulted in only transient reduction in stool shedding 
of Cryptosporidium and was not protective against disease (225).  
 cp23 is an immunodominant protein, geographically conserved among C. parvum 
isolates, is present in both the sporozoite and merozoite stages (178), and antibodies to it are 
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both gp15 and cp23 are associated with protection from diarrhea in immunocompetent adult 
human volunteers infected with Cryptosporidium (208, 232-234). Thus, a multivalent 
vaccine, incorporating multiple antigens or antigenic epitopes, may enhance protection 
against infection. For example a divalent cp23 and cp15 vaccine prolonged the prepatent 
period and decreased oocyst shedding in mice vaccinated with the divalent vaccine compared 
with vaccination with cp23 alone (223). Similarly a reverse vaccinology approach based on 
genome mining that included three antigens; the well characterised cp15, a calcium-activated 
apyrase involved in the invasion process of Cryptosporidium and profilin, an agonist of the 
innate immune system through its recognition by Toll-like receptors, induced specific and 
potent humoral and cellular immune responses in mice, however, further studies are 
necessary to verify the protection induced by these antigens (224). The development of an 
effective vaccine against Cryptosporidium is still a challenge and a better understanding of 




Recent developments have improved our understanding of both the genetics of and immune 
response in cryptosporidial infections. However, many knowledge gaps remain. Current 
diagnostic tests each have their limitations in cost, performance, differentiation of clinical 
significance, and assessment of co-infections with other pathogens. Inaccessability of 
diagnostic testing in non-industrialised has meant that the knowledge of the epidemiology of 
Cryptosporidium infection in early infancy is scarce, and as a result, the burden of 
cryptosporidiosis is under-reported and under-estimated, which reinforces ineffective clinical 
and public health management of Cryptosporidium. Rapid, cost-effective and reliable 
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detection, reporting and interpretation of results in the setting of multiple infections. With the 
recent improvements in cell culture and genetic manipulation, identification of novel or 
repurposed therapeutics should be radically transformed. Vaccines have the potential to 
reduce the significant burden of disease, but the extent and types of immunity necessary, and 
the methods by which to administer and induce protective immunity need further study.  
 
ACKNOWLEDGEMENTS 
The authors are grateful for funding for our current Cryptosporidium research from the 
Australian Research Council Linkage Grant number LP130100035. 
 
DISCLOSURES 
The authors have no potential conflict of interest to disclose.  
 
REFERENCES 
1. Monis PT & Thompson RCA. Cryptosporidium and Giardia – zoonoses: fact or 
fiction? Infect Genet Evol 2003; 3: 23-244.  
2. Hunter PR, Hadfield SJ, Wilkinson D, et al. Subtypes of Cryptosporidium parvum 
in humans and disease risk. Emerg Infect Dis; 2007 13: 82-88. 
3. Ryan U & Power M. Cryptosporidium species in Australian wildlife and domestic 
animals. Parasitol 2012; 139: 1673-1688.  
4. Xiao L. Molecular epidemiology of cryptosporidiosis: an update. Exp Parasitol 
2010; 124: 80-89. 
5. Kváč M, Saková K, Kvĕtoňová D, et al. Gastroenteritis caused by the 
Cryptosporidium hedgehog genotype in an immunocompetent man. J Clin 










This article is protected by copyright. All rights reserved. 
6. Ryan U, Fayer R & Xiao L. Cryptosporidium species in humans and animals: 
current understanding and research needs. Parasitol 2014; 141: 1667-1685. 
7. Costa J, Cruz C, Eiras JC & Saraiva A, Characterization of a Cryptosporidium 
scophthalmi-like isolate from farmed turbot (Scophthalmus maximus) using 
histological and molecular tools. Dis Aquat Organ 2016; In press. 
8. Li X, Pereira Md, Larsen R, Xiao C, et al. Cryptosporidium rubeyi n. sp. 
(Apicomplexa: Cryptosporidiidae) in multiple Spermophilus ground squirrel 
species. Int J Parasitol Parasites Wildl 2015; 4: 343-350. 
9. Ryan U, Paparini A, Tong K, et al. Cryptosporidium huwi n. sp. (Apicomplexa: 
Eimeriidae) from the guppy (Poecilia reticulata). Exp Parasitol 2015; 150: 31-35. 
10. Zahedi A, Paparini A, Jian F, Robertson I & Ryan U. Public health significance of 
zoonotic Cryptosporidium species in wildlife: critical insights into better drinking 
water management Int J Parasitol Parasites Wildl 2016; 5, 88e109. 
11. Holubová N, Sak B, Horčičková M, et al. Cryptosporidium avium n. sp. 
(Apicomplexa: Cryptosporidiidae) in birds. Parasitol Res 2016; 115:2243-2251. 
12. Kváč M, Havrdová N, Hlásková L, et al. Cryptosporidium proliferans n. sp. 
(Apicomplexa: Cryptosporidiidae): Molecular and biological evidence of cryptic 
species within gastric Cryptosporidium of mammals. PLoS One 2016; 
11:e0147090. 
13. Chalmers RM & Davies AP. Minireview: clinical cryptosporidiosis. Exp Parasitol 
2010; 124: 138-146.  
14. Bouzid M, Hunter PR, Chalmers RM & Tyler KM. Cryptosporidium pathogenicity 
and virulence. Clin Microbiol Rev 2013; 26: 115-134.  










This article is protected by copyright. All rights reserved. 
16. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal 
disease in infants and young children in developing countries (the Global Enteric 
Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382: 
209-222.  
17. Nasrin D, Wu Y, Blackwelder WC, et al. Health care seeking for childhood 
diarrhea in developing countries: evidence from seven sites in Africa and Asia. Am 
J Trop Med Hyg 2013; 89: 3-12.  
18. Breurec S, Vanel N, Bata P, et al. Etiology and Epidemiology of Diarrhea in 
Hospitalized Children from Low Income Country: A Matched Case-Control Study 
in Central African Republic. PLoS Negl Trop Dis 2016; 10: e0004283. 
19. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of 
community diarrhoea in developing countries: a multisite birth cohort study (MAL-
ED). Lancet Glob Health 2015; 3:e564-75. 
20. Shoultz DA, de Hostos EL & Choy RKM. Addressing Cryptosporidium infection 
among young children in low-income settings: The crucial role of new and existing 
drugs for reducing morbidity and mortality. PLoS Negl Trop Dis 2016; 10: 
e0004242. 
21. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the 
Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.  
22. Striepen B, Parasitic infections: Time to tackle cryptosporidiosis. Nature 2013; 
503: 189-191.  
23. Mølbak K, Andersen M, Aaby P, et al. Cryptosporidium infection in infancy as a 
cause of malnutrition: a community study from Guinea-Bissau, west Africa. Am J 










This article is protected by copyright. All rights reserved. 
24. Guerrant DI, Moore SR, Lima AA, et al. Association of early childhood diarrhea 
and cryptosporidiosis with impaired physical fitness and cognitive function four-
seven years later in a poor urban community in northeast Brazil. Am J Trop Med 
Hyg 1999; 61: 707-713. 
25. Kirkpatrick BD, Daniels MM, Jean SS, et al. Cryptosporidiosis stimulates an 
inflammatory intestinal response in malnourished Haitian children. J Infect Dis 
2002; 186: 94-101.  
26. Macfarlane DE & Horner-Bryce J. Cryptosporidiosis in well-nourished and 
malnourished children. Acta Paediatr Scand 1987; 76: 474-477. 
27. Sallon S, Deckelbaum RJ, Schmid II, Harlap S, Baras M & Spira DT. 
Cryptosporidium, malnutrition, and chronic diarrhea in children. Am J Dis Child 
1988; 142: 312-315. 
28. Bushen OY, Kohli A, Pinkerton RC, et al. Heavy cryptosporidial infections in 
children in northeast Brazil: comparison of Cryptosporidium hominis and 
Cryptosporidium parvum. Trans R Soc Trop Med Hyg 2007;101: 378-384. 
29. Checkley W, Gilman RH, Epstein LD, et al. Asymptomatic and symptomatic 
cryptosporidiosis: their acute effect on weight gain in Peruvian children. Am J 
Epidemiol 1997; 145: 156-163.  
30. Mondal D, Haque R, Sack RB, Kirkpatrick BD & Petri WA, Jr. Attribution of 
malnutrition to cause-specific diarrheal illness: evidence from a prospective study 
of preschool children in Mirpur, Dhaka, Bangladesh. Am J Trop Med Hyg 2009; 
80: 824-826.  
31. Quihui-Cota L, Lugo-Flores CM, Ponce-Martínez JA & Morales-Figueroa GG. 
Cryptosporidiosis: a neglected infection and its association with nutritional status 










This article is protected by copyright. All rights reserved. 
32. Fletcher S, Stark D, Harkness J & Ellis J. Enteric Protozoa in the Developed 
World: a Public Health Perspective. Clin Microbiol Rev 2012; 25: 420-449. 
33. Baldursson S & Karanis P. Waterborne transmission of protozoan parasites: 2004 
2010. Water Res 2011; 45: 6603-6614. 
34. Burnet JB, Penny C, Ogorzaly L & Cauchie HM. Spatial and temporal distribution 
of Cryptosporidium and Giardia in a drinking water resource: implications for 
monitoring and risk assessment. Sci Total Environ 2014; 472: 1023-1035.  
35. Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium hominis: 
experimental challenge of healthy adults. Am J Trop Med Hyg 2006; 75: 851-857. 
36. Okhuysen PC, Chappell CL, Crabb JH, Sterling CR & DuPont HL. Virulence of 
three distinct Cryptosporidium parvum isolates for healthy adults. J Infect Dis 
1999; 180: 1275-1281. 
37. Pouillot R, Beaudeau P, Denis JB & Derouin F. A quantitative risk assessment of 
waterborne cryptosporidiosis in France using second-order Monte Carlo 
simulation. Risk Anal 2004; 24: 1-17. 
38. Abubakar I, Aliyu SH, Arumugam C, Usman NK & Hunter PR. Treatment of 
cryptosporidiosis in immunocompromised individuals: systematic review and 
meta-analysis. Br J Clin Pharmacol 2007; 63: 387-393. 
39. Amadi B, Mwiya M, Sianongo S, et al. High dose prolonged treatment with 
nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian 
children: a randomised controlled trial. BMC Infect Dis 2009; 9: 195. 
40. Robertson, LJ, Bjorkman, C., Axen C & Fayer R. Cryptosporidiosis in farmed 
animals. In Cryptosporidium: parasite and disese, ed. Caccio SM & Widmer G, 
Springer: New York; 2014; 145-236. 










This article is protected by copyright. All rights reserved. 
42. Budu-Amoako E, Greenwood SJ, Dixon BR, Barkema HW & McClure JT. 
Foodborne illness associated with Cryptosporidium and Giardia from livestock. J 
Food Prot 2011; 74: 1944-1955.  
43. Sponseller JK, Griffiths JK & Tzipori S. 2014. The evolution of respiratory 
Cryptosporidiosis: evidence for transmission by inhalation. Clin Microbiol Rev 
2014; 27: 575-586.  
44. Schwabe CW. Veterinary medicine and human health. 1984. 3rd ed. Baltimore 
(MD): Williams and Wilkins. 
45. Chalmers RM & Katzer F. Looking for Cryptosporidium: the application of 
advances in detection and diagnosis. Trends Parasitol 2013; 29: 237-251.  
46. Checkley W, White AC Jr, Jaganath D, et al. A review of the global burden, novel 
diagnostics, therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect 
Dis 2015; 15: 85-94. 
47. Fall A, Thompson RC, Hobbs RP & Morgan-Ryan U. Morphology is not a reliable 
tool for delineating species within Cryptosporidium. J Parasitol 2003; 89: 399-
402. 
48. O'Donoghue PJ. Cryptosporidium and cryptosporidiosis in man and animals. Int J 
Parasitol 1995; 25: 139-195. 
49. Weber R, Bryan RT, Bishop HS, Wahlquist SP, Sullivan JJ & Juranek DD. 
Threshold of detection of Cryptosporidium oocysts in human stool specimens: 
evidence for low sensitivity of current diagnostic methods. J Clin Microbiol 1991; 
29: 1323-1327. 
50. Clavel A, Arnal AC, Sánchez EC, et al. Evaluation of the optimal number of faecal 
specimens in the diagnosis of cryptosporidiosis in AIDS and immunocompetent 










This article is protected by copyright. All rights reserved. 
51. Chalmers RM, Campbell BM, Crouch N, Charlett A & Davies AP. Comparison of 
diagnostic sensitivity and specificity of seven Cryptosporidium assays used in the 
UK. J Med Microbiol 2011; 60: 1598-1604.  
52. Ignatius R, Klemm T, Zander S, et al. Highly specific detection of 
Cryptosporidium spp. oocysts in human stool samples by undemanding and 
inexpensive phase contrast microscopy. Parasitol Res 2016; 115:1229-1234. 
53. Garcia LS & Shimizu RY. Evaluation of nine immunoassay kits (enzyme 
immunoassay and direct fluorescence) for detection of Giardia lamblia and 
Cryptosporidium parvum in human fecal specimens. J Clin Microbiol 1997; 35: 
1526-1529. 
54. Johnston SP, Ballard MM, Beach MJ, Causer L & Wilkins PP. Evaluation of three 
commercial assays for detection of Giardia and Cryptosporidium organisms in 
fecal specimens. J Clin Microbiol 2003; 41: 623-626. 
55. Youn S, Kabir M, Haque R & Petri WA Jr. Evaluation of a screening test for 
detection of Giardia and Cryptosporidium parasites. J Clin Microbiol 2009; 47: 
451-452. 
56. Robinson TJ, Cebelinski EA, Taylor C & Smith KE. Evaluation of the positive 
predictive value of rapid assays used by clinical laboratories in Minnesota for the 
diagnosis of cryptosporidiosis. Clin Infect Dis 2010; 50: e53-55. 
57. Agnamey P, Sarfati C, Pinel C, et al. Evaluation of four commercial rapid 
immunochromatographic assays for detection of Cryptosporidium antigens in stool 
samples: a blind multicenter trial. J Clin Microbiol 2011; 49: 1605-1607.  
58. Kang CD, Cao C, Lee J, Choi IS, Kim BW & Sim SJ. Surface plasmon resonance-
based inhibition assay for real-time detection of Cryptosporidium parvum oocyst. 










This article is protected by copyright. All rights reserved. 
59. Campbell GA & Mutharasan R. Near real-time detection of Cryptosporidium 
parvum oocyst by IgM-functionalized piezoelectric-excited millimeter-sized 
cantilever biosensor. Biosens Bioelectron 2008; 23: 1039-1045. 
60. Hadfield SJ, Robinson G, Elwin K & Chalmers RM. Detection and differentiation 
of Cryptosporidium spp. in human clinical samples by use of real-time PCR. J Clin 
Microbiol 2011; 49: 918-924. 
61. Elwin K, Robinson G, Hadfield SJ, Fairclough HV, Iturriza-Gómara M & 
Chalmers RM. A comparison of two approaches to extracting Cryptosporidium 
DNA from human stools as measured by a real-time PCR assay. J Microbiol 
Methods 2012; 89: 38-40. 
62. Yang R, Murphy C, Song Y, et al. Specific and quantitative detection and 
identification of Cryptosporidium hominis and C. parvum in clinical and 
environmental samples. Exp Parasitol 2013; 135: 142-147. 
63. Yang R, Jacobson C, Gardner G, et al. Longitudinal prevalence, oocyst shedding 
and molecular characterisation of Cryptosporidium species in sheep across four 
states in Australia. Vet Parasitol 2014; 200: 50-58.  
64. Taniuchi M, Sobuz SU, Begum S, et al. Etiology of diarrhea in Bangladeshi infants 
in the first year of life analyzed using molecular methods. J Infect Dis 2013; 208: 
1794-802. 
65. Van Lint P, Rossen JW, Vermeiren S, et al. Detection of Giardia lamblia, 
Cryptosporidium spp. and Entamoeba histolytica in clinical stool samples by using 











This article is protected by copyright. All rights reserved. 
66. Nurminen N, Juuti R, Oikarinen S, et al. High-throughput multiplex quantitative 
polymerase chain reaction method for Giardia lamblia and Cryptosporidium 
species detection in stool samples. Am J Trop Med Hyg 2015; 92: 1222-1226. 
67. Bridle H, Kersaudy-Kerhoas M, Miller B, et al. Detection of Cryptosporidium in 
miniaturised fluidic devices. Water Res 2012; 46: 1641-1661. 
68. Abrahamsen MS, Templeton TJ, Enomoto S, et al. Complete genome sequence of 
the apicomplexan, Cryptosporidium parvum. Science 2004; 304: 441-415.  
69. Ryan U & Hijjawi N. New developments in Cryptosporidium research. Int J 
Parasitol 2015; 45: 367-373. 
70. Miyamoto Y & Eckmann L. Drug Development Against the major diarrhea-
causing parasites of the small intestine, Cryptosporidium and Giardia. Front 
Microbiol 2015; 6: 1208. 
71. Morada M, Lee S, Gunther-Cummins L, et al. Continuous culture of 
Cryptosporidium parvum using hollow fiber technology. Int J Parasitol 2016; 46: 
21-29. 
72. Vinayak S, Pawlowic MC, Sateriale A, et al. Genetic modification of the diarrhoeal 
pathogen Cryptosporidium parvum. Nature 2015; 523: 477-480. 
73. Striepen B, Pruijssers AJ, Huang J, et al. Gene transfer in the evolution of parasite 
nucleotide biosynthesis. Proc Natl Acad Sci U S A 2004; 101: 3154-3159.  
74. Kirubakaran S, Gorla SK, Sharling L, et al. Structure-activity relationship study of 
selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. 
Bioorg Med Chem Lett 2012; 22: 1985-1988. 
75. Mandapati K, Gorla SK, House AL, et al. Repurposing Cryptosporidium inosine 
5'-monophosphate dehydrogenase inhibitors as potential antibacterial agents. ACS 










This article is protected by copyright. All rights reserved. 
76. Umejiego NN, Gollapalli D, Sharling L, et al. Targeting a prokaryotic protein in a 
eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. 
Chem Biol 2008; 15: 70-77.  
77. Maurya SK, Gollapalli DR, Kirubakaran S, et al. Triazole inhibitors of 
Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem 
2009; 52: 4623-4630. 
78. Macpherson IS, Kirubakaran S, Gorla SK, et al. The structural basis of 
Cryptosporidium-specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc 
2010; 132: 1230-1231. 
79. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L & Striepen B. A 
screening pipeline for antiparasitic agents targeting Cryptosporidium inosine 
monophosphate dehydrogenase. PLoS Negl Trop Dis 2010; 4: e794.  
80. Gorla SK, Kavitha M, Zhang M, et al. Selective and potent urea inhibitors of 
Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem. 
2012; 55: 7759-7771. 
81. Gorla SK, Kavitha M, Zhang M, et al. Optimization of benzoxazole-based 
inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J 
Med Chem 2013; 56: 4028-4043. 
82. Johnson CR, Gorla SK, Kavitha M, et al. Phthalazinone inhibitors of inosine-5'-
monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem 
Lett 2013; 23: 1004-1007. 
83. Jefferies R, Yang R, Woh CK, et al. Target validation of the inosine 
monophosphate dehydrogenase (IMPDH) gene in Cryptosporidium using 










This article is protected by copyright. All rights reserved. 
84. Kim Y, Makowska-Grzyska M, Gorla SK, et al. Structure of Cryptosporidium IMP 
dehydrogenase bound to an inhibitor with in vivo antiparasitic activity. Acta 
Crystallogr F Struct Biol Commun 2015; 71: 531-538. 
85. Li RJ, Wang YL, Wang QH, Huang WX, Wang J & Cheng MS. Binding mode of 
inhibitors and Cryptosporidium parvum IMP dehydrogenase: A combined ligand- 
and receptor-based study. SAR QSAR Environ Res 2015; 26: 421-438. 
86. Guo F, Zhang H, Fritzler JM, et al. Amelioration of Cryptosporidium parvum 
infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A 
synthetases. J Infect Dis 2014; 209: 1279-1287. 
87. Ndao M, Nath-Chowdhury M, Sajid M, et al. A cysteine protease inhibitor rescues 
mice from a lethal Cryptosporidium parvum infection. AntimicrobAgents 
Chemother 2013; 57: 6063-6073.  
88.      Adams CP & Brantner, VV. Estimating the cost of new drug development: is it 
really $802 million? Health Aff (Millwood) 2006; 25: 420-428. 
89.      Bessoff K, Spangenberg T, Foderaro JE, Jumani RS, Ward GE & Huston CD. 
Identification of Cryptosporidium parvum active chemical series by repurposing 
the open access malaria box. Antimicrob Agents Chemother 2014; 58: 2731-2739.  
90.      Bessoff K, Sateriale A, Lee KK & Huston CD. Drug repurposing screen reveals 
FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis 
that block Cryptosporidium parvum growth. Antimicrob Agents Chemother 2013; 
57: 1804-1814. 
91.     Debnath A, Ndao M & Reed SL. Reprofiled drug targets ancient protozoans: drug 










This article is protected by copyright. All rights reserved. 
92.     Appelbee AJ, Thompson RC & Olson ME. Giardia and Cryptosporidium in 
mammalian wildlife-current status and future needs. Trends Parasitol 2005; 21: 
370-376. 
93.      Ryan U & Xiao L. Taxonomy and molecular taxonomy. In Cryptosporidium: 
parasite and disease, ed. Caccio SM & Widmer G, Springer: New York; 2014; 3-
42. 
94.     Morgan UM, Xiao L, Hill BD, et al. Detection of the Cryptosporidium parvum 
"human" genotype in a dugong (Dugong dugon). J Parasitol 2000; 86: 1352-1354. 
95.     Smith HV, Nichols RA, Mallon M, et al. Natural Cryptosporidium hominis 
infections in Scottish cattle. Vet Rec 2005; 156: 710-711. 
96.    Giles M, Chalmers R, Pritchard G, Elwin K, Mueller-Doblies D & Clifton-Hadley 
F. Cryptosporidium hominis in a goat and a sheep in the UK. Vet Rec 2009; 164: 
24-25. 
97.    Abeywardena H, Jex AR, Nolan MJ, et al. Genetic characterisation of 
Cryptosporidium and Giardia from dairy calves: discovery of species/genotypes 
consistent with those found in humans. Infect Genet Evol 2012; 12: 1984-1993. 
98.   Ye J, Xiao L, Ma J, Guo M, Liu L & Feng Y. Anthroponotic enteric parasites in 
monkeys in public park, China. Emerg Infect Dis 2012; 18: 1640-1643.  
99.    Connelly L, Craig BH, Jones B & Alexander CL. Genetic diversity of 
Cryptosporidium spp. within a remote population of Soay Sheep on St. Kilda 
Islands, Scotland. Appl Environ Microbiol 2013; 79: 2240-2246. 
100. Karim MR, Zhang S, Jian F, et al. Multilocus typing of Cryptosporidium spp. and 











This article is protected by copyright. All rights reserved. 
101. Koinari M, Lymbery AJ & Ryan UM. Cryptosporidium species in sheep and goats 
from Papua New Guinea. Exp Parasitol 2014; 141: 134-137.  
102. Parsons MB, Travis D, Lonsdorf EV, et al. Epidemiology and molecular 
characterization of Cryptosporidium spp. in humans, wild primates, and 
domesticated animals in the Greater Gombe Ecosystem, Tanzania. PLoS Negl Trop 
Dis 2015; 9: e0003529. 
103. Koinari M, Karl S, Ng-Hublin J, Lymbery AJ & Ryan UM. Identification of novel 
and zoonotic Cryptosporidium species in fish from Papua New Guinea. Vet 
Parasitol 2013; 198: 1-9. 
104. Reid A, Lymbery A, Ng J, Tweedle S & Ryan U. Identification of novel and 
zoonotic Cryptosporidium species in marine fish. Vet Parasitol 2010; 168: 190-
195. 
105. Gibson-Kueh S, Yang R, Thuy NT, Jones JB, Nicholls PK & Ryan U. The 
molecular characterization of an Eimeria and Cryptosporidium detected in Asian 
seabass (Lates calcarifer) cultured in Vietnam. Vet Parasitol 2011; 181: 91-96. 
106. Certad G, Dupouy-Camet J, Gantois N, et al. Identification of Cryptosporidium 
Species in Fish from Lake Geneva (Lac Léman) in France. PLoS One 2015; 10: 
e0133047. 
107. Gatei W, Suputtamongkol Y, Waywa D, et al. Zoonotic species of 
Cryptosporidium are as prevalent as the anthroponotic in HIV-infected patients in 
Thailand. Ann Trop Med Parasitol 2002; 96: 797-802. 
108. Cama VA, Ross JM, Crawford S, et al. Differences in clinical manifestations 
among Cryptosporidium species and subtypes in HIV-infected persons. J Infect Dis 










This article is protected by copyright. All rights reserved. 
109. Chalmers RM, Robinson G, Elwin K, et al. Cryptosporidium sp. rabbit genotype, a 
newly identified human pathogen. Emerg Infect Dis 2009; 15: 829-830. 
110. Robinson G, Chalmers RM, Stapleton C, et al. A whole water catchment approach 
to investigating the origin and distribution of Cryptosporidium species. J Appl 
Microbiol 2011; 111: 717-730.  
111. Puleston RL, Mallaghan CM, Modha DE, et al. The first recorded outbreak of 
cryptosporidiosis due to Cryptosporidium cuniculus (formerly rabbit genotype), 
following a water quality incident. J Water Health 2014; 12: 41-50. 
112. Chalmers RM, Elwin K, Hadfield SJ & Robinson G. Sporadic human 
cryptosporidiosis caused by Cryptosporidium cuniculus, United Kingdom, 2007-
2008. Emerg Infect Dis 2011; 17: 536-538. 
113. Elwin K, Hadfield SJ, Robinson G & Chalmers RM. The epidemiology of sporadic 
human infections with unusual cryptosporidia detected during routine typing in 
England and Wales, 2000-2008. Epidemiol Infect 2012; 140: 673-683. 
114. Koehler AV, Whipp MJ, Haydon SR & Gasser RB. Cryptosporidium cuniculus-
new records in human and kangaroo in Australia. Parasit Vectors 2014; 7: 492. 
115. Martínez-Ruiz R, de Lucio A, Fuentes I, Carmena D. Autochthonous 
Cryptosporidium cuniculus infection in Spain: First report in a symptomatic 
paediatric patient from Madrid. Enferm Infecc Microbiol Clin 2016; In press. 
116. Lucio-Forster A, Griffiths JK, Cama VA, Xiao L & Bowman DD. Minimal 
zoonotic risk of cryptosporidiosis from pet dogs and cats. Trends Parasitol 2010; 
26: 174-179. 
117. Guyot K, Follet-Dumoulin A, Lelièvre E, et al. Molecular characterization of 











This article is protected by copyright. All rights reserved. 
118. Gatei W, Ashford RW, Beeching NJ, Kamwati SK, Greensill J & Hart CA. 
Cryptosporidium muris infection in an HIV-infected adult, Kenya. Emerg Infect 
Dis 2002; 8: 204-206. 
119. Tiangtip R & Jongwutiwes S. Molecular analysis of Cryptosporidium species 
isolated from HIV-infected patients in Thailand. Trop Med Int Health 2002; 7: 
357-364. 
120. Gatei W, Greensill J, Ashford RW, et al. Molecular analysis of the 18S rRNA gene 
of Cryptosporidium parasites from patients with or without human 
immunodeficiency virus infections living in Kenya, Malawi, Brazil, the United 
Kingdom, and Vietnam. J Clin Microbiol 2003; 41: 1458-1462. 
121. Palmer CJ, Xiao L, Terashima A, et al. Cryptosporidium muris, a rodent pathogen, 
recovered from a human in Perú. Emerg Infect Dis 2003; 9: 1174-1176. 
122. Gatei W, Wamae CN, Mbae C, et al. Cryptosporidiosis: prevalence, genotype 
analysis, and symptoms associated with infections in children in Kenya. Am J Trop 
Med Hyg 2006; 75: 78-82. 
123. Leoni F, Amar C, Nichols G, Pedraza-Díaz S & McLauchlin J. Genetic analysis of 
Cryptosporidium from 2414 humans with diarrhoea in England between 1985 and 
2000. J Med Microbiol 2006; 55: 703-707. 
124. Muthusamy D, Rao SS, Ramani S, et al. Multilocus genotyping of 
Cryptosporidium sp. isolates from human immunodeficiency virus-infected 
individuals in South India. J Clin Microbiol 2006; 44: 632-634. 
125. Al-Brikan FA, Salem HS, Beeching N & Hilal N. Multilocus genetic analysis of 











This article is protected by copyright. All rights reserved. 
126. Neira O P, Muñoz S N, Wilson L G, Barthel M ME, Rosales L MJ & Henríquez R 
C. Cryptosporidium species in immunodeficient and immunocompetent patients of 
Valparaíso: a descriptive study. Rev Chilena Infectol 2012; 29: 63-71. 
127. Hasajová A, Valenčáková A, Malčeková B, et al. Significantly higher occurrence 
of Cryptosporidium infection in Roma children compared with non-Roma children 
in Slovakia. Eur J Clin Microbiol Infect Dis 2014; 33: 1401-1406. 
128. Spanakos G, Biba A, Mavridou A & Karanis P. Occurrence of Cryptosporidium 
and Giardia in recycled waters used for irrigation and first description of 
Cryptosporidium parvum and C. muris in Greece. Parasitol Res 2015; 114: 1803-
1810. 
129. Petrincová A, Valenčáková A, Luptáková L, et al. Molecular characterization and 
first report of Cryptosporidium genotypes in human population in the Slovak 
Republic. Electrophoresis 2015; 36: 2925-2930. 
130. Chappell CL, Okhuysen PC, Langer-Curry RC, Lupo PJ, Widmer G & Tzipori S. 
Cryptosporidium muris: infectivity and illness in healthy adult volunteers. Am J 
Trop Med Hyg 2015; 92: 50-55. 
131. Jiang Y, Ren J, Yuan Z, et al. Cryptosporidium andersoni as a novel predominant 
Cryptosporidium species in outpatients with diarrhea in Jiangsu Province, China. 
BMC Infect Dis 2014; 14: 555. 
132. Liu H, Shen Y, Yin J, et al. Prevalence and genetic characterization of 
Cryptosporidium, Enterocytozoon, Giardia and Cyclospora in diarrheal outpatients 
in China. BMC Infect Dis 2014; 14:25. 
133. Li N, Xiao L, Alderisio K, et al. Subtyping Cryptosporidium ubiquitum, a zoonotic 










This article is protected by copyright. All rights reserved. 
134. Feltus DC, Giddings CW, Schneck BL, Monson T, Warshauer D & McEvoy JM. 
Evidence supporting zoonotic transmission of Cryptosporidium spp. in Wisconsin. 
J Clin Microbiol 2006; 44: 4303-4308. 
135. Feng Y, Alderisio KA, Yang W, et al. Cryptosporidium genotypes in wildlife from 
a New York watershed. Appl Environ Microbiol 2007; 73: 6475-6483.  
136. Robinson G, Elwin K & Chalmers RM. Unusual Cryptosporidium genotypes in 
human cases of diarrhea. Emerg Infect Dis 2008; 14: 1800-1802. 
137. ANOFEL Cryptosporidium National Network. Laboratory based surveillance for 
Cryptosporidium in France, 2006-2009. Euro Surveill 2010; 15: 19642. 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19642. 
138. Elwin K, Hadfield SJ, Robinson G & Chalmers RM. The epidemiology of sporadic 
human infections with unusual cryptosporidia detected during routine typing in 
England and Wales, 2000-2008. Epidemiol Infect 2012; 140: 673-683.  
139. Insulander M, Silverlås C, Lebbad M, Karlsson L, Mattsson JG & Svenungsson B. 
Molecular epidemiology and clinical manifestations of human cryptosporidiosis in 
Sweden. Epidemiol Infect 2013; 141: 1009-1020.  
140. Lebbad M, Beser J, Insulander M, et al. Unusual cryptosporidiosis cases in 
Swedish patients: extended molecular characterization of Cryptosporidium 
viatorum and Cryptosporidium chipmunk genotype I. Parasitology 2013; 140: 
1735-1740.  
141. Ng-Hublin JS, Combs B, Mackenzie B & Ryan U. Human cryptosporidiosis 
diagnosed in Western Australia: a mixed infection with Cryptosporidium 
meleagridis, the Cryptosporidium mink genotype, and an unknown 










This article is protected by copyright. All rights reserved. 
142. Ebner J, Koehler AV, Robertson G, et al. Genetic analysis of Giardia and 
Cryptosporidium from people in Northern Australia using PCR-based tools. Infect 
Genet Evol 2015; 36: 389-395. 
143. Guo Y, Cebelinski E, Matusevich C, et al. Subtyping novel zoonotic pathogen 
Cryptosporidium chipmunk genotype I. J Clin Microbiol 2015; 53: 1648-1654. 
144. Widerström M, Schönning C, Lilja M, et al. Large outbreak of Cryptosporidium 
hominis infection transmitted through the public water supply, Sweden. Emerg 
Infect Dis 2014; 20: 581-589.  
145. Jacob P, Henry A, Meheut G, Charni-Ben-Tabassi N, Ingrand V, Helmi K. Health 
risk assessment related to waterborne pathogens from the river to the tap. Int J 
Environ Res Public Health 2015; 12: 2967-2983.  
146. Goh S, Reacher M, Casemore DP, et al. Sporadic cryptosporidiosis, North 
Cumbria, England, 1996-2000. Emerg Infect Dis 2004; 10: 1007-1015. 
147. Leach CT, Koo FC, Kuhls TL, et al. Prevalence of Cryptosporidium parvum 
infection in children along the Texas-Mexico border and associated risk factors. 
Am J Trop Med Hyg 2000; 62: 656-661. 
148. Khalakdina A, Vugia DJ, Nadle J, Rothrock GA & Colford JM Jr. Is drinking 
water a risk factor for endemic cryptosporidiosis? A case-control study in the 
immunocompetent general population of the San Francisco Bay Area. BMC Public 
Health 2003; 3: 11. 
149. Roy SL, DeLong SM, Stenzel SA, et al. Risk factors for sporadic cryptosporidiosis 
among immunocompetent persons in the United States from 1999 to 2001. J Clin 










This article is protected by copyright. All rights reserved. 
150. Sarkar R, Ajjampur SS, Prabakaran AD, et al. Cryptosporidiosis among children in 
an endemic semiurban community in southern India: does a protected drinking 
water source decrease infection? Clin Infect Dis 2013; 57: 398-406. 
151. Checkley W, Epstein LD, Gilman RH, Black RE, Cabrera L & Sterling CR. Effects 
of Cryptosporidium parvum infection in Peruvian children: growth faltering and 
subsequent catch-up growth. Am J Epidemiol 1998; 148: 497-506.  
152. Muchiri JM, Ascolillo L, Mugambi M, et al. Seasonality of Cryptosporidium 
oocyst detection in surface waters of Meru, Kenya as determined by two isolation 
methods followed by PCR. J Water Health 2009; 7: 67-75.  
153. Bridgman SA, Robertson RM, Syed Q, Speed N, Andrews N & Hunter PR.  
Outbreak of cryptosporidiosis associated with a disinfected groundwater supply. 
Epidemiol Infect 1995; 115: 555-566. 
154. Jagai JS, Castronovo DA, Monchak J & Naumova EN. Seasonality of 
cryptosporidiosis: A meta-analysis approach. Environ Res 2009; 109: 465-478. 
155. Young I, Smith BA & Fazil A. A systematic review and meta-analysis of the 
effects of extreme weather events and other weather-related variables on 
Cryptosporidium and Giardia in fresh surface waters. J Water Health 2015; 13: 1-
17. 
156. Pachauri RK. Climate change 2007. In Pachauri RK, Reisinger A. (eds). Synthesis 
report. Contribution of Working Groups I, II and III to the Fourth Assessment 
Report. Geneva: IPCC, 2008. 
157. Schijven J, Bouwknegt M, de Roda Husman AM, et al. A decision support tool to 
compare waterborne and foodborne infection and/or illness risks associated with 










This article is protected by copyright. All rights reserved. 
158. Hoyer AB, Schladow SG & Rueda FJ. A hydrodynamics-based approach to 
evaluating the risk of waterborne pathogens entering drinking water intakes in a 
large, stratified lake. Water Res 2015 83, 227-236.  
159. Haas CN, Gerba CP. Quantitative Microbiological Risk Assessment. New York: 
Wiley and Sons, 1999. 
160. Schijven JF & de Roda Husman, AM. Effect of climate changes on waterborne 
disease in the Netherlands. Water Sci Technol 2005; 51: 79-87. 
161. Davies CM, Kaucner C, Deere D & Ashbolt NJ. Recovery and enumeration of 
Cryptosporidium parvum from animal fecal matrices. Appl Environ Microbiol 
2003; 69: 2842-2847. 
162. Chaidez C, Soto M, Gortares P & Mena K. Occurrence of Cryptosporidium and 
Giardia in irrigation water and its impact on the fresh produce industry. Int J 
Environ Health Res 2005; 15: 339-345. 
163. Huang DB & Zhou J. Effect of intensive handwashing in the prevention of 
diarrhoeal illness among patients with AIDS: a randomized controlled study. J Med 
Microbiol 2007; 56: 659-663. 
164. Lee MB & Greig JD. A review of gastrointestinal outbreaks in schools: effective 
infection control interventions. J Sch Health 2010; 80: 588-598.  
165. Hill A, Nally P, Chalmers RM, Pritchard GC & Giles M. Quantitative risk 
assessment for zoonotic transmission of Cryptosporidium parvum infection 
attributable to recreational use of farmland. Zoonoses Public Health 2011; 58: 323-
333.  
166. Tumwine JK, Kekitiinwa A, Bakeera-Kitaka S, et al. Cryptosporidiosis and 










This article is protected by copyright. All rights reserved. 
concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg 
2005; 73: 921-925. 
167. Mbae CK, Nokes DJ, Mulinge E, Nyambura J, Waruru A & Kariuki S. Intestinal 
parasitic infections in children presenting with diarrhoea in outpatient and inpatient 
settings in an informal settlement of Nairobi, Kenya. BMC Infect Dis 2013; 13: 
243. 
168. Tellevik MG, Moyo SJ, Blomberg B, et al. Prevalence of Cryptosporidium 
parvum/hominis, Entamoeba histolytica and Giardia lamblia among young 
children with and without diarrhea in Dar es Salaam, Tanzania. PLoS Negl Trop 
Dis 2015; 9: e0004125.  
169. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human 
immunodeficiency virus-associated opportunistic infections in the United States in 
the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5-14. 
170. Bonatti H, Barroso LF 2nd, Sawyer RG, Kotton CN & Sifri CD. Cryptosporidium 
enteritis in solid organ transplant recipients: multicenter retrospective evaluation of 
10 cases reveals an association with elevated tacrolimus concentrations. Transpl 
Infect Dis 2012; 14: 635-648.  
171. Desoubeaux G, Caumont C, Passot C, et al. Two cases of opportunistic parasite 
infections in patients receiving alemtuzumab. J Clin Pathol 2012; 65: 92-95. 
172. Amadi B, Kelly P, Mwiya M, et al. Intestinal and systemic infection, HIV, and 
mortality in Zambian children with persistent diarrhea and malnutrition. J Pediatr 
Gastroenterol Nutr 2001; 32: 550-554.  
173. Haque R, Mondal D, Karim A, et al. Prospective case-control study of the 
association between common enteric protozoal parasites and diarrhea in 










This article is protected by copyright. All rights reserved. 
174. Moore SR, Lima NL, Soares AM, et al. Prolonged episodes of acute diarrhea 
reduce growth and increase risk of persistent diarrhea in children. 
Gastroenterology 2010; 139: 1156-1164.  
175. Mondal D, Minak J, Alam M, et al. Contribution of enteric infection, altered 
intestinal barrier function, and maternal malnutrition to infant malnutrition in 
Bangladesh. Clin Infect Dis 2012; 54: 185-192.  
176. Houpt ER, Bushen OY, Sam NE, et al. Short report: asymptomatic 
Cryptosporidium hominis infection among human immunodeficiency virus-
infected patients in Tanzania. Am J Trop Med Hyg 2005; 73: 520-522. 
177. Korpe PS, Liu Y, Siddique A, et al. Breast milk parasite-specific antibodies and 
protection from amebiasis and cryptosporidiosis in Bangladeshi infants: a 
prospective cohort study. Clin Infect Dis 2013; 56: 988-992. 
178. Mead JR. Prospects for immunotherapy and vaccines against Cryptosporidium. 
Hum Vaccin Immunother 2014; 10: 1505-1513. 
179. Ludington JG & Ward HD. Systemic and mucosal immune responses to 
Cryptosporidium vaccine development. Curr Trop Med Rep 2015; 2: 171-180. 
180. Okhuysen PC, Chappell CL, Crabb J, Valdez LM, Douglass ET, DuPont HL. 
Susceptibility and serologic response of healthy adults to reinfection with 
Cryptosporidium parvum. Infect Immun 1998; 66: 441-443.  
181. Chappell CL, Okhuysen PC, Sterling CR, Wang C, Jakubowski W & Dupont HL. 
Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. 
parvum serum immunoglobulin G. Am J Trop Med Hyg 1999; 60: 157-164.  
182. Petry F, Jakobi V & Tessema TS. Host immune response to Cryptosporidium 










This article is protected by copyright. All rights reserved. 
183. McDonald V, Korbel DS, Barakat FM, Choudhry N & Petry F. Innate immune 
responses against Cryptosporidium parvum infection. Parasite Immunol 2013; 35: 
55-64. 
184. Takeuchi D, Jones VC, Kobayashi M, Suzuki F. Cooperative role of macrophages 
and neutrophils in host anti-protozoan resistance in mice acutely infected with 
Cryptosporidium parvum. Infect Immun 2008; 76:3657-63. 
185. Borad A & Ward H. Human immune responses in cryptosporidiosis. Future 
Microbiol 2010; 5: 507-519.  
186. Robinson P, Okhuysen PC, Chappell CL, et al. Expression of IL-15 and IL-4 in 
IFN-gamma-independent control of experimental human Cryptosporidium parvum 
infection. Cytokine 2001; 15: 39-46.  
187. Dann SM, Wang HC, Gambarin KJ, et al. Interleukin-15 activates human natural 
killer cells to clear the intestinal protozoan Cryptosporidium. J Infect Dis 2005; 
192: 1294-302. 
188. McDonald V, Pollok RC, Dhaliwal W, Naik S, Farthing MJ & Bajaj-Elliott M. A 
potential role for interleukin-18 in inhibition of the development of 
Cryptosporidium parvum. Clin Exp Immunol 2006; 145: 555-562. 
189. Ehigiator HN, McNair N & Mead JR. Cryptosporidium parvum: the contribution of 
Th1-inducing pathways to the resolution of infection in mice. Exp Parasitol 2007; 
115: 107-113.  
190. Choudhry N, Petry F, van Rooijen N & McDonald V. A protective role for 
interleukin 18 in interferon gamma-mediated innate immunity to Cryptosporidium 










This article is protected by copyright. All rights reserved. 
191. Bedi B, McNair NN, Forster I & Mead JR. IL-18 cytokine levels modulate innate 
immune responses and cryptosporidiosis in mice. J Eukaryot Microbiol 2015; 62: 
44-50.  
192. Chen XM, O'Hara SP, Nelson JB, et al. Multiple TLRs are expressed in human 
cholangiocytes and mediate host epithelial defense responses to Cryptosporidium 
parvum via activation of NF-kappaB. J Immunol 2005; 175: 7447-7456. 
193. Barrier M, Lacroix-Lamandé S, Mancassola R, et al. Oral and intraperitoneal 
administration of phosphorothioate oligodeoxynucleotides leads to control of 
Cryptosporidium parvum infection in neonatal mice. J Infect Dis 2006; 193: 1400-
1407. 
194. Costa LB, JohnBull EA, Reeves JT, et al. Cryptosporidium-malnutrition 
interactions: mucosal disruption, cytokines and TLR signaling in a weaned murine 
model. J Parasitol 2011; 97: 1113-1120. 
195. O’Hara S, Tietz Bogert PS, Trussoni CE, Chen X & Larusso NF. Tlr4 Promotes 
Cryptosporidium parvum clearance in a mouse model of biliary cryptosporidiosis. 
J Parasitol 2011; 97: 813-821. 
196. Lantier L, Drouet F, Guesdon W, et al. Poly(I:C)-induced protection of neonatal 
mice against intestinal Cryptosporidium parvum infection requires an additional 
TLR5 signal provided by the gut flora. J Infect Dis 2014; 209: 457-467. 
197. Perez-Cordon G, Yang G, Zhou B, et al. Interaction of Cryptosporidium parvum 
with mouse dendritic cells leads to their activation and parasite transportation to 
mesenteric lymph nodes. Pathogens Dis 2014; 70: 17-27. 
198. Yang Z, Fu Y, Gong P, et al. Bovine TLR2 and TLR4 mediate Cryptosporidium 











This article is protected by copyright. All rights reserved. 
199. Chen XM, Splinter PL, O’Hara SP & LaRusso NF. A cellular micro-RNA, let-7i, 
regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune 
responses against Cryptosporidium parvum infection. J Biol Chem 2007; 282: 
28929-2838.  
200. Zhou R, Hu G, Liu J, Gong AY, Drescher KM & Chen XM. NF-kappaB p65-
dependent transactivation of miRNA genes following Cryptosporidium parvum 
infection stimulates epithelial cell immune responses. PLoS Pathog 2009; 5: 
e1000681. 
201. Hu G, Zhou R, Liu J, Gong AY & Chen XM. MicroRNA-98 and let-7 regulate 
expression of suppressor of cytokine signaling 4 in biliary epithelial cells in 
response to Cryptosporidium parvum infection. J Infect Dis 2010; 202: 125-35.  
202. Gong AY, Zhou R, Hu G, et al. MicroRNA-221 controls expression of intercellular 
adhesion molecule-1 in epithelial cells in response to Cryptosporidium parvum 
infection. Int J Parasitol. 2011; 41: 397-403.  
203. Zhou R, Gong AY, Eischeid AN & Chen XM. miR-27b targets KSRP to 
coordinate TLR4-mediated epithelial defense against Cryptosporidium parvum 
infection. PLoS Pathog 2012; 8: e1002702.  
204. Xie H, Lei N, Gong AY, Chen XM & Hu G. Cryptosporidium parvum induces 
SIRT1 expression in host epithelial cells through downregulating let-7i. Hum 
Immunol 2014; 75: 760-765.  
205. Kelly P, Jack DL, Naeem A, et al. Mannose-binding lectin is a component of 
innate mucosal defense against Cryptosporidium parvum in AIDS. 










This article is protected by copyright. All rights reserved. 
206. Kirkpatrick BD, Huston CD, Wagner D, et al. Serum mannose-binding lectin 
deficiency is associated with cryptosporidiosis in young Haitian children. Clin 
Infect Dis 2006; 43: 289-294.  
207. Carmolli M, Duggal P, Haque R, et al. Deficient serum mannose-binding lectin 
levels and MBL2 polymorphisms increase the risk of single and recurrent 
Cryptosporidium infections in young children. J Infect Dis 2009; 200: 1540-1547.  
208. Moss DM, Chappell CL, Okhuysen PC, et al. The antibody response to 27-, 17-, 
and 15-kDa Cryptosporidium antigens following experimental infection in humans. 
J Infect Dis 1998; 178: 827-833. 
209. O’Connor RM, Shaffie R, Kang G & Ward HD. Cryptosporidiosis in patients with 
HIV/AIDS. AIDS 2011; 25: 549-560. 
210. Singh I, Carville A & Tzipori S. Cryptosporidiosis in rhesus macaques challenged 
during acute and chronic phases of SIV infection. AIDS Res Hum Retroviruses 
2011; 27: 989-997.  
211. Sheoran A, Wiffin A, Widmer G, Singh P & Tzipori S. Infection with 
Cryptosporidium hominis provides incomplete protection of the host against 
Cryptosporidium parvum. J Infect Dis 2012; 205: 1019-1023. 
212. Savy M, Edmond K, Fine PE, et al. Landscape analysis of interactions between 
nutrition and vaccine responses in children. J Nutr 2009; 139: 2154S-218S. 
213. Steinhagen F, Kinjo T, Bode C & Klinman DM. TLR-based immune adjuvants. 
Vaccine. 2011; 29: 3341-3355. 
214. Preidis GA, Wang HC, Lewis DE, et al. Seropositive human subjects produce 
interferon gamma after stimulation with recombinant Cryptosporidium hominis 










This article is protected by copyright. All rights reserved. 
215. Egorov AI, Montuori Trimble LM, Ascolillo L, et al. Recent diarrhea is associated 
with elevated salivary IgG responses to Cryptosporidium in residents of an eastern 
Massachusetts community. Infection 2010; 38: 117-123.  
216. Ajjampur SS, Sarkar R, Allison G, et al. Serum IgG response to Cryptosporidium 
immunodominant antigen gp15 and polymorphic antigen gp40 in children with 
cryptosporidiosis in South India. Clin Vaccine Immunol 2011; 18: 633-639. 
217. Allison GM, Rogers KA, Borad A, et al. Antibody responses to the 
immunodominant Cryptosporidium gp15 antigen and gp15 polymorphisms in a 
case-control study of cryptosporidiosis in children in Bangladesh. Am J Trop Med 
Hyg 2011; 85: 97-104.  
218. Sarkar R, Ajjampur SS, Muliyil J, Ward H, Naumova EN & Kang G. Serum IgG 
responses and seroconversion patterns to Cryptosporidium gp15 among children in 
a birth cohort in south India. Clin Vaccine Immunol 2012; 19: 849-854.  
219. Lazarus RP, Ajjampur SS, Sarkar R, et al. Serum anti-cryptosporidial gp15 
antibodies in mothers and children less than 2 years of age in India. Am J Trop Med 
Hyg 2015; 93: 931-938. 
220. Jenkins MC & Fayer R. Cloning and expression of cDNA encoding an antigenic 
Cryptosporidium parvum protein. Mol Biochem Parasitol 1995; 71: 149-152. 
221. Hong-Xuan H, Lei C, Cheng-Min W, et al. Expression of the recombinant fusion 
protein CP15-23 of Cryptosporidium parvum and its protective test. J Nanosci 
Nanotechnol 2005; 5: 1292-1296. 
222. Wang C, Luo J, Amer S, et al. Multivalent DNA vaccine induces protective 
immune responses and enhanced resistance against Cryptosporidium parvum 










This article is protected by copyright. All rights reserved. 
223. Liu K, Zai D, Zhang D, et al. Divalent Cp15-23 vaccine enhances immune 
responses and protection against Cryptosporidium parvum infection. Parasite 
Immunol 2010; 32: 335-344. 
224. Manque PA, Tenjo F, Woehlbier U, et al. Identification and immunological 
characterization of three potential vaccinogens against Cryptosporidium species. 
Clin Vaccine Immunol 2011; 18: 1796-1802.  
225. Roche JK, Rojo AL, Costa LB, et al. Intranasal vaccination in mice with an 
attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of 
Cryptosporidium: impact of malnutrition with preservation of cytokine secretion. 
Vaccine 2013; 31: 912-918.  
226. Ehigiator HN, Romagnoli P, Priest JW, Secor WE & Mead JR. Induction of murine 
immune responses by DNA encoding a 23-kDa antigen of Cryptosporidium 
parvum. Parasitol Res 2007; 101: 943-950.  
227. Benitez AJ, McNair N & Mead JR. Oral immunization with attenuated Salmonella 
enterica serovar Typhimurium encoding Cryptosporidium parvum Cp23 and Cp40 
antigens induces a specific immune response in mice. Clin Vaccine Immunol 2009; 
16: 1272-1278.  
228. Boulter-Bitzer JI, Lee H & Trevors JT. Molecular targets for detection and 
immunotherapy in Cryptosporidium parvum. Biotechnol Adv 2007; 25: 13-44. 
229. Wanyiri JW, Kanyi H, Maina S, et al. Cryptosporidiosis in HIV/AIDS patients in 
Kenya: clinical features, epidemiology, molecular characterization and antibody 
responses. Am J Trop Med Hyg 2014; 91: 319-328.  
230. Sagodira S, Buzoni-Gatel D, Iochmann S, Naciri M & Bout D. Protection of kids 
against Cryptosporidium parvum infection after immunization of dams with CP15-










This article is protected by copyright. All rights reserved. 
231. Priest JW, Li A, Khan M, et al. Enzyme immunoassay detection of antigen-specific 
immunoglobulin g antibodies in longitudinal serum samples from patients with 
cryptosporidiosis. Clin Diagn Lab Immunol 2001; 8: 415-243. 
232. Chappell CL, Okhuysen PC, Sterling CR, Wang C, Jakubowski W & Dupont HL. 
Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. 
parvum serum immunoglobulin G. Am J Trop Med Hyg 1999; 60: 157-164. 
233. Riggs MW. Recent advances in cryptosporidiosis: the immune response. Microbes 
Infect 2002; 4: 1067-1080.  
234. Frost FJ, Tollestrup K, Craun GF, Fairley CK, Sinclair MI & Kunde TR. Protective 
immunity associated with a strong serological response to a Cryptosporidium-
specific antigen group, in HIV-infected individuals. J Infect Dis 2005; 192: 618-
621. 
 
 
 
